1. Imatinib Mesylate Exerted Antitumor Effect by Promoting Infiltration of Effector T Cells in Tumor
   Aya Hirata et al, 2022, Biological and Pharmaceutical Bulletin CrossRef
2. Verruca Vulgaris Eruption Arising in the Setting of a Tyrosine Kinase Inhibitor
   Ahava Muskat et al, 2022, Cureus CrossRef
3. Dynamic changes in the levels of sCD62L and SPARC in chronic myeloid leukaemia patients during imatinib treatment
   Mahmoud Mohamed Elkholy et al, 2022, Journal of Clinical Pharmacy and Therapeutics CrossRef
4. Treatment-Free Remission—A New Aim in the Treatment of Chronic Myeloid Leukemia
   Paulina Kwaśnik et al, 2021, Journal of Personalized Medicine CrossRef
5. Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias
   Julian Swatler et al, 2021, Cancers CrossRef
6. A Role for the Non-Receptor Tyrosine Kinase Abl2/Arg in Experimental Neuroinflammation
   Freja Aksel Jacobsen et al, 2018, Journal of Neuroimmune Pharmacology CrossRef
7. Cardiovascular oncology: exploring the effects of targeted cancer therapies on atherosclerosis
   Tom T.P. Seijkens et al, 2018, Current Opinion in Lipidology CrossRef
8. Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review
   Dimitrios C. Ziogas et al, 2021, Frontiers in Oncology CrossRef
9. Molecular Changes in Chronic Myeloid Leukemia During Tyrosine Kinase Inhibitors Treatment. Focus on Immunological Pathways
   Michał Janowski et al, 2022, OncoTargets and Therapy CrossRef
10. Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review
    Chunmou Li et al, 2022, Frontiers in Oncology CrossRef
11. The Binary Classification of Protein Kinases
    Zeev Elkoshi, 2021, Journal of Inflammation Research CrossRef